Today: 18 January 2026
Subscribe
Browse Category

Biotech News 4 December 2025 - 9 December 2025

CSL Limited (ASX:CSL) Stock Outlook 2026: Is the Biotech Giant Finally a Buy After a 35% Sell-Off?

CSL Limited (ASX:CSL) Stock Outlook 2026: Is the Biotech Giant Finally a Buy After a 35% Sell-Off?

As of 9 December 2025 CSL Limited, long considered one of the most reliable growth names on the ASX, has just lived through one of the ugliest years in its listed history. After profit downgrades, a delayed spin-off, falling US vaccination rates and a shareholder revolt over executive pay, the stock is trading far below its early‑2025 highs. Yet underneath…
9 December 2025
····
Wave Life Sciences (WVE) Soars 147% on Obesity Drug Breakthrough and $250M Offering: What to Know Before the December 9 Open

Wave Life Sciences (WVE) Soars 147% on Obesity Drug Breakthrough and $250M Offering: What to Know Before the December 9 Open

Wave Life Sciences Ltd. (NASDAQ: WVE) just delivered one of the wildest biotech moves of 2025. On Monday, December 8, 2025, the stock rocketed after the company reported positive Phase 1 obesity drug data for WVE‑007 and simultaneously launched a $250 million equity offering. With the next U.S. trading session set to open on Tuesday, December 9, investors are trying…
9 December 2025
···
Gilead Sciences (GILD) Stock Today: Price, Fresh News and Analyst Outlook on December 8, 2025

Gilead Sciences (GILD) Stock Today: Price, Fresh News and Analyst Outlook on December 8, 2025

As of Monday, December 8, 2025, Gilead Sciences, Inc. (NASDAQ: GILD) sits near the upper end of its 52‑week range, supported by strong HIV franchises, new long‑acting prevention drugs, high‑profile cancer data at ASH 2025 and a steady dividend. At the same time, investors are weighing slowing COVID‑19 sales, competitive oncology pressures and policy risk. Below is a structured look…
8 December 2025
···
Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics, Inc. (NASDAQ: NRIX) is back in the spotlight. On December 8, 2025, the biotech stock surged roughly 20% intraday after the company released new Phase 1 data for its Bruton’s tyrosine kinase (BTK) degrader bexobrutideg (NX‑5948) in blood cancers at the American Society of Hematology (ASH) Annual Meeting and scheduled a corporate webcast for this evening. MarketBeat The…
8 December 2025
····
Biggest Stock Gainers Today: Biotech Breakouts and IBM–Confluent Deal Lead U.S. Market Movers (December 8, 2025)

Biggest Stock Gainers Today: Biotech Breakouts and IBM–Confluent Deal Lead U.S. Market Movers (December 8, 2025)

U.S. stocks traded mostly flat on Monday as Wall Street headed into a crucial Federal Reserve meeting, but under the surface the tape was anything but quiet. While the S&P 500 and Dow Jones Industrial Average hovered around unchanged and the Nasdaq 100 eked out a small gain, small‑cap and high‑beta names ripped higher, led by a wave of biotech…
8 December 2025
····
VKTX Stock Forecast 2025–2026: Can Viking Therapeutics’ Obesity Drug Pipeline Really Double the Share Price?

VKTX Stock Forecast 2025–2026: Can Viking Therapeutics’ Obesity Drug Pipeline Really Double the Share Price?

Viking Therapeutics (NASDAQ: VKTX) has quietly become one of the most closely watched small-cap names in the weight-loss drug trade. As of the last trading session on Friday, December 5, 2025, VKTX closed at $38.55, giving the company a market capitalization of roughly $4.3–4.4 billion. Viking Therapeutics InvestorRoom Yet Wall Street’s consensus 12‑month price targets sit in the high‑$80s to…
7 December 2025
···
NVAX Stock Today: Can Novavax Turn Regulatory Turmoil and Activist Pressure into a Comeback?

NVAX Stock Today: Can Novavax Turn Regulatory Turmoil and Activist Pressure into a Comeback?

Data and news current as of 7 December 2025. NVAX stock price now: where Novavax stands in December 2025 Novavax, Inc. (NASDAQ: NVAX) closed on Friday, 5 December 2025 at $6.91 per share, giving the vaccine maker a market value of around $1.1 billion. Novavax Investor Relations Over the last year, NVAX has slipped roughly 20%, according to data from…
7 December 2025
····
Moderna (MRNA) Stock: French Study Sparks Rally After FDA Shock – Latest News, Analyst Forecasts and 2026 Outlook

Moderna (MRNA) Stock: French Study Sparks Rally After FDA Shock – Latest News, Analyst Forecasts and 2026 Outlook

Updated: December 6, 2025 Moderna, Inc. (NASDAQ: MRNA) has just had one of its most dramatic weeks of 2025. Shares plunged early in the week after news that the U.S. Food and Drug Administration (FDA) may tighten vaccine approval standards, then rebounded sharply on Friday after a massive French real‑world study reaffirmed the safety and effectiveness of its COVID‑19 vaccine.…
6 December 2025
···
IonQ Stock (IONQ) on December 5, 2025: Quantum Breakthroughs, Biotech Deals, Big Money Flows and 2026 Forecast

IonQ Stock (IONQ) on December 5, 2025: Quantum Breakthroughs, Biotech Deals, Big Money Flows and 2026 Forecast

IonQ, Inc. (NYSE: IONQ) is back in the spotlight today after another burst of volatility that has pushed the stock to around the low‑$50s per share as of December 5, 2025. Different data sources show IONQ trading in the $51–55 range intraday, with notable pre‑market activity and heavy options volume. CoinCodex That’s happening against a backdrop of: Below is a…
5 December 2025
···
Biomea Fusion (BMEA) Stock Jumps on Durable Diabetes Drug Data: Outlook, Analyst Targets and Key Risks as of December 5, 2025

Biomea Fusion (BMEA) Stock Jumps on Durable Diabetes Drug Data: Outlook, Analyst Targets and Key Risks as of December 5, 2025

Biomea Fusion, Inc. (NASDAQ: BMEA) is back in the spotlight after the company reported long‑term data showing that its experimental diabetes drug icovamenib (formerly BMF‑219) can deliver durable blood‑sugar control many months after patients stop taking it. The new results, presented at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) in Los Angeles, pushed Biomea Fusion’s…
5 December 2025
···
Amgen (AMGN) Stock Near Record Highs on Obesity Drug Hopes – Is It Still a Buy in December 2025?

Amgen (AMGN) Stock Near Record Highs on Obesity Drug Hopes – Is It Still a Buy in December 2025?

Updated: December 4, 2025 Amgen Inc. (NASDAQ: AMGN) has quietly turned into one of 2025’s standout large‑cap healthcare winners. The biotech heavyweight is trading just below fresh 52‑week highs, powered by a clean sweep of earnings beats, a deepening obesity‑drug story around its MariTide program, and full FDA approval for its lung‑cancer therapy Imdelltra. At the same time, investors are…
4 December 2025
····
Regeneron (REGN) Price Target Hits $1,057 as BMO and Canaccord Lift Forecasts on Dupixent Growth

Regeneron (REGN) Price Target Hits $1,057 as BMO and Canaccord Lift Forecasts on Dupixent Growth

Published: December 4, 2025 Key Takeaways Wall Street Re‑rates Regeneron After Big Run — and Bigger Dupixent Story Regeneron Pharmaceuticals has suddenly become one of the most hotly debated large‑cap biotechs on Wall Street. On Thursday, December 4, 2025, multiple analyst moves and fresh data reshaped the Regeneron (REGN) stock narrative: Taken together, these moves signal that, despite a sharp…
4 December 2025
····
1 … 3 4 5 6 7 … 12

Stock Market Today

  • Nvidia stock muted after China blocks H200 shipments; traders eye earnings and AI-chip roadmap
    January 18, 2026, 1:53 PM EST. NVIDIA shares closed down 0.41% to $186.23 on Friday after a Financial Times report that Chinese customs blocked shipments of the H200 AI processor. Suppliers paused output as the halt looms over Nvidia's supply chain. With markets closed for MLK Day, focus shifts to Tuesday's session and Nvidia's Feb. 25 results. Analysts at Wolfe Research keep Nvidia on the Alpha List, citing a ramp for Blackwell and Rubin chips; they see upside to 2026 revenue if the trend holds. Options activity could amplify moves ahead of expiration. A pause that drags into a formal ban would delay shipments; a temporary pause could ease near-term pressure. The broader semis index rose, but the China hinge remains.
Go toTop